TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Cost-effectiveness of Booklet-based Self-management of Dizziness in Primary Care, With and Without Expert Telephone Support
Brief Summary: The investigators primary aim is to test whether or not provision of the self-help booklet teaching VR exercises, with up to one hour of telephone support from a vestibular therapist, will be more effective than routine care in reducing symptoms in dizzy patients in primary care. The investigators will also explore the extent to which patients may benefit from the self-help booklet without support. The investigators will determine whether these models of delivery are less costly than routine care of dizzy patients, as they should reduce the number of patients seeking referral to secondary care for unnecessary assessments.


Options:
A: Arm Label: Routine Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Booklet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-treatment booklet | Arm Label: Booklet &Therapist Support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-treatment booklet, Behavioral: Remote telephone support | Intervention Type: BEHAVIORAL; Name: Self-treatment booklet; Assigned to Arm(s): Booklet, Booklet &Therapist Support | Intervention Type: BEHAVIORAL; Name: Remote telephone support; Assigned to Arm(s): Booklet &Therapist Support
B: Arm Label: SVD-tailored Integrative Psychotherapy (IPT); Type: EXPERIMENTAL; Interventions: Behavioral: SVD-tailored Integrative Psychotherapy (IPT) | Arm Label: Self-help group (SHG); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-help group (SHG) | Intervention Type: BEHAVIORAL; Name: SVD-tailored Integrative Psychotherapy (IPT); Assigned to Arm(s): SVD-tailored Integrative Psychotherapy (IPT) | Intervention Type: BEHAVIORAL; Name: Self-help group (SHG); Assigned to Arm(s): Self-help group (SHG)
C: Arm Label: activity group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: occupational therapy based activity training programs | Arm Label: exercise group; Type: EXPERIMENTAL; Interventions: Procedure: Physiotherapy based exercise training programs | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: occupational therapy based activity training programs; Assigned to Arm(s): activity group | Intervention Type: PROCEDURE; Name: Physiotherapy based exercise training programs; Assigned to Arm(s): exercise group
D: Arm Label: BI + VR + CBT; Type: EXPERIMENTAL; Interventions: Behavioral: BI + VR + CBT, Behavioral: BI + phone calls | Arm Label: BI + phone calls; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BI + VR + CBT, Behavioral: BI + phone calls | Intervention Type: BEHAVIORAL; Name: BI + VR + CBT; Assigned to Arm(s): BI + VR + CBT, BI + phone calls | Intervention Type: BEHAVIORAL; Name: BI + phone calls; Assigned to Arm(s): BI + VR + CBT, BI + phone calls

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part)
Brief Summary: This trial is extension part of the P04280 (placebo-controlled, double-blind, randomized study of chronic treatment with infliximab in approximately 140 patients, NCT00202852). This study will be conducted at 6 study centers in South Korea. After completion of the last follow-up visit at Week 30 and code break in main double-blind trial, subjects randomized to the placebo group and those who were treated with an infliximab-containing regimen who maintained clinical response at the time of study completion will be provided with open-label infliximab for treatment of their conditions and additional safety data will be collected.


Options:
A: Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1
C: Arm Label: Placebo followed by Certolizumab Pegol (CZP); Type: OTHER; Interventions: Other: Placebo, Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Arm Label: Certolizumab Pegol (CZP); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 200 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 400 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP)
D: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part)
Brief Summary: This trial is extension part of the P04280 (placebo-controlled, double-blind, randomized study of chronic treatment with infliximab in approximately 140 patients, NCT00202852). This study will be conducted at 6 study centers in South Korea. After completion of the last follow-up visit at Week 30 and code break in main double-blind trial, subjects randomized to the placebo group and those who were treated with an infliximab-containing regimen who maintained clinical response at the time of study completion will be provided with open-label infliximab for treatment of their conditions and additional safety data will be collected.


Options:
A: Arm Label: 10 mg Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 15 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 20 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 25 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 10 mg Methotrexate (MTX), 15 mg MTX, 20 mg MTX, 25 mg MTX
B: Arm Label: Group I: Placebo + Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Arm Label: Group II: Golimumab + Methotrexate (MTX); Type: PLACEBO_COMPARATOR; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: DRUG; Name: methotrexate (MTX); Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX)
C: Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): N/A
D: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part)
Brief Summary: This trial is extension part of the P04280 (placebo-controlled, double-blind, randomized study of chronic treatment with infliximab in approximately 140 patients, NCT00202852). This study will be conducted at 6 study centers in South Korea. After completion of the last follow-up visit at Week 30 and code break in main double-blind trial, subjects randomized to the placebo group and those who were treated with an infliximab-containing regimen who maintained clinical response at the time of study completion will be provided with open-label infliximab for treatment of their conditions and additional safety data will be collected.


Options:
A: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate
C: Arm Label: Certolizumab pegol 200 mg (CDP870); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg (CDP870) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Tocilizumab 162 mg sc; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab 162 mg | Arm Label: Placebo sc; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tocilizumab 162 mg; Assigned to Arm(s): Tocilizumab 162 mg sc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo sc

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma
Brief Summary: Primary:

To evaluate if progression-free survival from first treatment to progression or death during second-line therapy (total PFS) of sorafenib followed by sunitinib is superior compared to sunitinib followed by sorafenib.

Secondary:

1. Time from first treatment to progression during second-line therapy (total TTP)
2. Time to first-line treatment failure (progression, death, discontinuation due to toxicity) descriptively in each arm
3. PFS in first-line and second-line treatment, descriptively
4. Overall survival, descriptively (data cut-off same as for primary endpoint)
5. Disease Control Rate (DCR); Response rates in first-line and in second-line (CR, PR, SD according to RECIST criteria)
6. Cardiotoxicity analysis by means of echocardiography and NT-pro BNP with an interim analysis after 100 patients of each arm have completed the study
7. Safety and tolerability


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cediranib Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cediranib Placebo; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tarceva (erlotinib HCl); Assigned to Arm(s): N/A
C: Arm Label: Pembrolizumab+Axitinib Combination Therapy; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Axitinib | Arm Label: Sunitinib Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab+Axitinib Combination Therapy | Intervention Type: DRUG; Name: Axitinib; Assigned to Arm(s): Pembrolizumab+Axitinib Combination Therapy | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib Monotherapy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib (Sutent) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar) | Intervention Type: DRUG; Name: Sunitinib (Sutent); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sorafenib (Nexavar); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma
Brief Summary: Primary:

To evaluate if progression-free survival from first treatment to progression or death during second-line therapy (total PFS) of sorafenib followed by sunitinib is superior compared to sunitinib followed by sorafenib.

Secondary:

1. Time from first treatment to progression during second-line therapy (total TTP)
2. Time to first-line treatment failure (progression, death, discontinuation due to toxicity) descriptively in each arm
3. PFS in first-line and second-line treatment, descriptively
4. Overall survival, descriptively (data cut-off same as for primary endpoint)
5. Disease Control Rate (DCR); Response rates in first-line and in second-line (CR, PR, SD according to RECIST criteria)
6. Cardiotoxicity analysis by means of echocardiography and NT-pro BNP with an interim analysis after 100 patients of each arm have completed the study
7. Safety and tolerability


Options:
A: Arm Label: Sunitinib 4/2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib 4/2 | Arm Label: Sunitinib 2/1; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib 2/1 | Intervention Type: DRUG; Name: Sunitinib 2/1; Assigned to Arm(s): Sunitinib 2/1 | Intervention Type: DRUG; Name: Sunitinib 4/2; Assigned to Arm(s): Sunitinib 4/2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib (Sutent) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar) | Intervention Type: DRUG; Name: Sunitinib (Sutent); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sorafenib (Nexavar); Assigned to Arm(s): 2
C: Arm Label: Atezolizumab and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab, Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multi-Center, Randomized, Open Label, Trial to Evaluate the Safety, Tolerability, and Biological Activity of 2 Dosing Schedules of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
Brief Summary: The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.


Options:
A: Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Belimumab | Intervention Type: BIOLOGICAL; Name: Belimumab; Assigned to Arm(s): Belimumab 10 mg/kg
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Belimumab 4 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Beimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Belimumab 20 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 4 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Beimumab 10 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 20 mg/kg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg
D: Arm Label: Belimumab Q2WKS; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 100 mg SC | Arm Label: Belimumab 3X/WK; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 100 mg SC | Intervention Type: DRUG; Name: Belimumab 100 mg SC; Assigned to Arm(s): Belimumab Q2WKS | Intervention Type: DRUG; Name: Belimumab 100 mg SC; Assigned to Arm(s): Belimumab 3X/WK

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: IVC CLAMP: Infrahepatic Inferior Vena Cava Clamping During Hepatectomy - A Randomized Controlled Trial
Brief Summary: Intraoperative blood loss is a major concern during hepatic resection, as it has been shown to adversely affect patients' perioperative outcome. Reduction of central venous pressure during parenchymal transection has been shown to effectively lower liver hemorrhage. While CVP reduction is mainly achieved via fluid restriction and diuretics, dehydration may impair organ function. Moreover, it may lead to hemodynamic instability, particularly in case of severe bleeding. For this reason the technique of infrahepatic inferior vena cava clamping has been suggested which is able to lower CVP without the need for fluid restriction.

In the present study the two strategies to reduce CVP and by this intraoperative bleeding, namely fluid restriction and inferior vena cava clamping are compared with intraoperative blood loss as primary endpoint.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Infrahepatic inferior vena cava clamping | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No infrahepatic inferior vena cava clamping | Intervention Type: PROCEDURE; Name: Infrahepatic inferior vena cava clamping; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: No infrahepatic inferior vena cava clamping; Assigned to Arm(s): B
B: N/A
C: Arm Label: Sangustop; Type: EXPERIMENTAL; Interventions: Device: Sangustop | Arm Label: Tachosil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tachosil | Intervention Type: DEVICE; Name: Sangustop; Assigned to Arm(s): Sangustop | Intervention Type: DRUG; Name: Tachosil; Assigned to Arm(s): Tachosil
D: Arm Label: Fibrin Pad; Type: EXPERIMENTAL; Interventions: Biological: Fibrin Pad | Arm Label: Standard of Care; Type: OTHER; Interventions: Procedure: Standard of Care | Intervention Type: BIOLOGICAL; Name: Fibrin Pad; Assigned to Arm(s): Fibrin Pad | Intervention Type: PROCEDURE; Name: Standard of Care; Assigned to Arm(s): Standard of Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Sleep-Disordered Breathing With Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients With Heart Failure
Brief Summary: The purpose of this trial is to evaluate the long-term effects and cost-effectiveness of adaptive servo-ventilation (ASV) on the mortality and morbidity of patients with stable heart failure due to left ventricular systolic dysfunction, already receiving optimal medical therapy, who have sleep disordered breathing (SDB) that is predominantly central sleep apnea. Assumptions: the intervention reduces the hazard rate by 20%. The event rate in the control group is 35% in the first year. It is assumed that the hazard rate is constant over time.


Options:
A: Arm Label: MV ASV+OMT; Type: EXPERIMENTAL; Interventions: Device: MV ASV, Drug: Optimized Medical Treatment | Arm Label: OMT only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimized Medical Treatment | Intervention Type: DEVICE; Name: MV ASV; Assigned to Arm(s): MV ASV+OMT | Intervention Type: DRUG; Name: Optimized Medical Treatment; Assigned to Arm(s): MV ASV+OMT, OMT only
B: Arm Label: Bilevel; Type: ACTIVE_COMPARATOR; Interventions: Device: Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany) | Arm Label: Servoventilation; Type: ACTIVE_COMPARATOR; Interventions: Device: servoventilation (Somnovent CR, Weinmann, Hamburg, Germany) | Intervention Type: DEVICE; Name: Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany); Assigned to Arm(s): Bilevel | Intervention Type: DEVICE; Name: servoventilation (Somnovent CR, Weinmann, Hamburg, Germany); Assigned to Arm(s): Servoventilation
C: Arm Label: Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Europe: AutoSet CS (USA: VPAP Adapt SV) | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Europe: AutoSet CS (USA: VPAP Adapt SV); Assigned to Arm(s): Treatment Group
D: Arm Label: ASV mode; Type: ACTIVE_COMPARATOR; Interventions: Device: VPAP Adapt SV | Arm Label: CPAP mode; Type: ACTIVE_COMPARATOR; Interventions: Device: VPAP Adapt SV | Intervention Type: DEVICE; Name: VPAP Adapt SV; Assigned to Arm(s): ASV mode, CPAP mode

Answer: C